6.00

3.63% 0.21

Pre-market: 6.29 0.29 +4.83%

Third Harmonic Bio Inc (THRD)

Overview News Price History Option Chain Financials Discussions Forecast

Third Harmonic Bio Inc stock is traded at $6.00, with a volume of 376.72K. It is up +3.63% in the last 24 hours and down -44.65% over the past month. Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.

Previous Close:

$5.79

Open:

$5.87

24h Volume:

376.72K

Relative Volume:

1.70

Market Cap:

$270.35M

Revenue:

Net Income/Loss:

$-32.74M

P/E Ratio:

-7.3171

EPS:

-0.82

Net Cash Flow:

$-24.89M

1W Performance:

+0.17%

1M Performance:

-44.65%

6M Performance:

-49.20%

1Y Performance:

-38.21%

1-Day Range:

$5.82

$6.38

1-Week Range:

$5.5977

$6.38

52-Week Range:

$5.5977

$16.94

Third Harmonic Bio Inc Stock (THRD) Company Profile

Name

Third Harmonic Bio Inc

Sector

Healthcare (1176)

Industry

Biotechnology (685)

Phone

(209) 727-2457

Address

1700 MONTGOMERY STREET, SAN FRANCISCO

Employee

Twitter

Next Earnings Date

Latest SEC Filings

THRD's Discussions on Twitter

Compare THRD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
THRD Third Harmonic Bio Inc	6.00	270.35M	0	-32.74M	-24.89M	-0.82
VRTX Vertex Pharmaceuticals Inc	427.89	110.19B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	687.80	75.58B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	647.39	38.71B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	264.99	34.18B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.25	28.11B	3.30B	-501.07M	1.03B	-2.1146

Third Harmonic Bio Inc Stock (THRD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-09-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jun-18-24	Initiated	Stifel	Buy
Jun-07-24	Initiated	Raymond James	Outperform
Dec-16-22	Downgrade	Jefferies	Buy → Hold
Dec-15-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-10-22	Initiated	Cowen	Outperform
Oct-10-22	Initiated	Jefferies	Buy
Oct-10-22	Initiated	Morgan Stanley	Overweight

View All

Third Harmonic Bio Inc Stock (THRD) Latest News

Jan 18, 2025

Trend Tracker for (THRD) - Stock Traders Daily

Jan 18, 2025

Jan 14, 2025

Jefferies cuts Third Harmonic stock target to $7 from $15 By Investing.com - Investing.com Canada

Jan 14, 2025

Jan 13, 2025

Third Harmonic Bio shares drop to lowest since 2023 By Investing.com - Investing.com Canada

Jan 13, 2025

Jan 10, 2025

Third Harmonic Bio stock hits 52-week low at $8.04 - Investing.com India

Jan 10, 2025

Jan 09, 2025

Dermata Therapeutics Inc (DRMA): Major Improvements, Worth A Look - Stocks Register

Jan 09, 2025

Jan 08, 2025

Stifel maintains positive outlook on Celldex and Third Harmonic stocks By Investing.com - Investing.com Canada

Jan 08, 2025

Revance gains as it plans to enter talks with Teoxane on likely superior bid (RVNC:NASDAQ) - Seeking Alpha

Jan 08, 2025

Jan 07, 2025

Learn to Evaluate (THRD) using the Charts - Stock Traders Daily

Jan 07, 2025

Pre-market Movers: CDT, NARI, GDTC, NARI... - RTTNews

Jan 07, 2025

Jan 06, 2025

Revance Therapeutics jumps after Teoxane offers $3.60 a share (NASDAQ:RVNC) - Seeking Alpha

Jan 06, 2025

Jan 03, 2025

Third Harmonic Bio's SWOT analysis: oral KIT inhibitor stock shows promise - Investing.com Australia

Dec 17, 2024

Dec 10, 2024

Third Harmonic Bio's SWOT analysis: stock outlook brightens on clinical progress - Investing.com India

Dec 10, 2024

Stock Market Analysis & Tools for Investors - Seeking Alpha

Dec 10, 2024

Third Harmonic Bio's SWOT analysis: stock outlook brightens on clinical progress By Investing.com - Investing.com South Africa

Dec 10, 2024

Dec 09, 2024

Revance Therapeutics plunges after Crown Labs cuts takeover price in half - Seeking Alpha

Dec 09, 2024

Dec 05, 2024

Atlas Venture Announces $450 Million Fund XIV - Yahoo Finance

Dec 05, 2024

Nov 26, 2024

How the (THRD) price action is used to our Advantage - Stock Traders Daily

Nov 26, 2024

Nov 25, 2024

Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference - Marketscreener.com

Nov 25, 2024

Third Harmonic Bio to Present at Evercore HealthCONx Conference in December | THRD Stock News - StockTitan

Nov 25, 2024

Nov 20, 2024

Wall Street Analysts Believe Third Harmonic Bio, Inc. (THRD) Could Rally 26.67%: Here's is How to Trade - MSN

Nov 20, 2024

Nov 19, 2024

Aclaris stock soars for second day on licensing deal, analyst upgrades (NASDAQ:ACRS) - Seeking Alpha

Nov 19, 2024

Nov 15, 2024

(THRD) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 15, 2024

RA Capital Management Reduces Stake in Third Harmonic Bio Inc - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Significant Stake Increase by T. Rowe Price in Third Harmonic Bi - GuruFocus.com

Nov 14, 2024

Nov 12, 2024

Revance Therapeutics jumps after Crown Laboratories tender offer extended again - Seeking Alpha

Nov 12, 2024

Nov 11, 2024

Vertiv Rises 13% in a Month: Time for Investors to Buy the Stock? - MSN

Nov 11, 2024

Shiba Inu (SHIB) Price Rises 53% but Hits Rejection at Key Ascending Resistance Level - MSN

Nov 11, 2024

Nov 08, 2024

Canopy Growth stock on watch after Q2 results (CGC:NASDAQ) - Seeking Alpha

Nov 08, 2024

Third Harmonic Bio Reports Q3 2024 Financial Results - TipRanks

Nov 08, 2024

Nov 07, 2024